Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Disclosed are crystal of thyroid hormone β receptor agonist, process for preparing the same and use thereof. The crystal with basically no hygroscopicity, a relatively small crystal particle size and a relatively large drug specific surface area can improve the dissolution rate of drugs, is beneficial to the absorption of drugs and improves the bioavailability.

A method for preparing the cyclic phosphonate compound of Formula I

##STR00001##

is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality.

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

Provided herein are compounds of the formula: wherein the variables are defined herein. The present disclosure also provides pharmaceutical compositions comprising the compounds disclosed herein as well as methods of treatment using the compounds and/or compositions disclosed herein. Such compounds and compositions may be used, for example, for the inhibition of enolase enzymes.

A method for preparing the cyclic phosphonate compound of Formula I ##STR00001##
is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.